Immune Checkpoint Inhibition (Tremelimumab and/or MEDI4736) in Combination With Radiation Therapy in Patients With Unresectable Pancreatic Cancer
Clinical trial NCT02311361 · COMPLETED
Trial details
- NCT number
- NCT02311361
- Sponsor
- National Cancer Institute (NCI)
- Status
- COMPLETED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2015-03-25
- Primary completion
- 2019-10-23
- Enrollment
- 65
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.